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Abstract
Background: Diagnosis of urogenital schistosomiasis by microscopy and serological tests may be elusive in travelers due to
low egg load and the absence of seroconversion upon arrival. There is need for a more sensitive diagnostic test. Therefore,
we developed a real-time PCR targeting the Schistosoma haematobium-specific Dra1 sequence.
Methodology/Principal Findings: The PCR was evaluated on urine (n = 111), stool (n = 84) and serum samples (n = 135), and
one biopsy from travelers and migrants with confirmed or suspected schistosomiasis. PCR revealed a positive result in 7/7
urine samples, 11/11 stool samples and 1/1 biopsy containing S. haematobium eggs as demonstrated by microscopy and in
22/23 serum samples from patients with a parasitological confirmed S. haematobium infection. S. haematobium DNA was
additionally detected by PCR in 7 urine, 3 stool and 5 serum samples of patients suspected of having schistosomiasis
without egg excretion in urine and feces. None of these suspected patients demonstrated other parasitic infections except
one with Blastocystis hominis and Entamoeba cyst in a fecal sample. The PCR was negative in all stool samples containing S.
mansoni eggs (n = 21) and in all serum samples of patients with a microscopically confirmed S. mansoni (n = 22), Ascaris
lumbricoides (n = 1), Ancylostomidae (n = 1), Strongyloides stercoralis (n = 1) or Trichuris trichuria infection (n = 1). The PCR
demonstrated a high specificity, reproducibility and analytical sensitivity (0.5 eggs per gram of feces).
Conclusion/Significance: The real-time PCR targeting the Dra1 sequence for S. haematobium-specific detection in urine,
feces, and particularly serum, is a promising tool to confirm the diagnosis, also during the acute phase of urogenital
schistosomiasis.
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Introduction
Urogenital schistosomiasis due to Schistosoma haematobium is a
serious underestimated public health problem. It is endemic in 53
countries of the African continent and of the Middle East [1,2].
Adult worms live in the capillary plexus of the bladder and other
parts of the urino-genital system and eggs are excreted in the urine
and occasionally found in feces.
Diagnosis of S. haematobium infections is traditionally done by
microscopy but is often unreliable due to the circadian and day-to-
day variations in egg excretion, and to low parasite load, especially
in the traveler. Antibody-based assays are useful to confirm
infection, but do not distinguish active infection from past
exposure, and false-negative results occur, mainly in S. haematobium
infections. Antibody tests are usually negative during acute
symptomatic schistosomiasis. Assays that detect circulating anti-
gens seem very promising in the early phase of infection but still
lack sensitivity in the diagnosis of light infections [3,4,5,6].
Recently, we developed a genus-specific real-time PCR
(further called ‘genusPCR’) that sensitively detect all human
infectious Schistosoma species in feces and urine [7]. The
genusPCR was not able to detect schistosome DNA in serum
although molecular analysis of serum is of interest in acute
schistosomiasis before detectable levels of eggs are excreted
[8–12]. In 2009, Wichmann and colleagues [10] described a
real-time PCR, targeting a highly repeated 121-bp sequence
of S. mansoni (named Sm1-7) to detect cell-free schistosome
DNA in serum. This was proven successful in acute and
chronic S. mansoni infection, but not so much in S. haematobium
infection. To fill that gap, we developed a real-time PCR
specific for the diagnosis of S. haematobium in serum samples.
The real-time PCR targets Dra1, a S. haematobium-specific 121-
bp repeat sequence originally described by Hamburger et al.
and present in hundreds to thousands of copies and
representing at least 15% of its genome [13]. We first tested
this PCR (further called ‘draPCR’) on urine and feces samples
to evaluate its species-specificity and its performance in
comparison with microscopy, and then on serum samples to
determine its potential as diagnostic tool for acute phase
schistosomiasis.
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Methods
Ethics statement
The diagnostic procedures described in this manuscript are part
of the standard diagnostic work-up of patients suspected of
schistosomiasis. All samples were routine diagnostic samples from
patients presenting at the Institute of Tropical Medicine (ITM,
Antwerp, Belgium) policlinic and were stored after completion of
the routine tests. The ITM has the policy that sample left-overs of
patients presenting at the ITM policlinic can be used for research
unless the patients explicitly state their objection. The Institutional
Review Board of ITM approved the institutional policy of this
presumed consent as long as patients’ identity is not disclosed to
third parties. All data have been analysed anonymously.
Clinical samples
PCR analysis was retrospectively performed between January
and October 2012 on samples that were stored at ,218uC
between 2006 and 2012. In total, 330 clinical samples from 187
patients were analysed of which 110 urine, 84 stool, 126 serum, 9
blood samples, and one biopsy sample. The samples were from
145 travelers and 42 migrants that presented at the outpatient
clinic of the ITM, Antwerp, Belgium. The patients travelled to
Africa (92.5%), Asia (5.4%), the Middle East (1.6%) and South-
America (0.5%). The median time interval between return and
sample collection was 82 days (varying from 1 day to 1851 days).
Based on laboratory findings, the stool, urine and/or serum
samples were selected from patients with confirmed (n= 47) or
suspected (n = 140) intestinal or urogenital schistosomiasis. Con-
firmed cases were defined as patients with eggs of S. mansoni or S.
haematobium as determined by microscopy. Individuals with a
confirmed infection were treated with praziquantel after diagnosis.
Serum of confirmed cases was collected before or at the time of
egg detection, or after treatment. Suspected cases were patients
who presented after a stay in an endemic region with clinical
symptoms and/or with an increase in eosinophils (.0.456109/L),
a positive serology (IHA titer $1/160 or positive ELISA), the
presence of Charcot-leyden crystals in feces or hematuria (.7
RBC/mL) or who travelled together with a confirmed case.
DNA extraction
As previously described [7,14], DNA was extracted with the
QIAamp DNA stool mini kit (Qiagen Benelux, Venlo, The
Netherlands) from 1 gram of feces that was dissolved into 5 mL
ASL buffer (Qiagen). An 200 ml urine sediment was processed for
DNA extraction with the QIAamp DNA mini kit (Qiagen) after
centrifugation of 10 mL of urine and three wash/centrifugation
steps. For DNA extraction of serum with the QIAamp DNAMIDI
kit (Qiagen) or by phenol/chloroform, 1 to 2 mL of serum was
used [7].
Control samples
Positive control DNA of S. mansoni and S. haematobium were
kindly provided by Dr. T. Huyse (ITM/KUL, Belgium). Positive
control DNA of S. intercalatum and S. guineensis were kindly provided
by Dr. F. Allan from SCAN at the Natural History Museum
(London, UK) [15]. DNA was extracted from one adult worm and
used in a 1/100 dilution (,0.1 ng/mL). Positive control DNA of S.
mekongi was obtained from a stool sample of a patient seen at ITM,
containing 50 eggs per gram (EPG). Positive control DNA of S.
japonicum derived from cercariae spotted on FTA filter paper kindly
provided by Dr. J.P. Webster (London, UK).
Primer and probe design
The highly repetitive Dra1 sequence of S. haematobium (Accession
number DQ157698.1) was selected as target and primers were
identical to those described [13] (Sh-FW 5-gatctcacctatcagac-
gaaac-39; Sh-RV 59-tcacaacgatacgaccaac-39). An additional fluo-
rescent labeled hydrolysis probe was developed (Sh-probe 59-
tgttggtggaagtgcctgtttcgcaa-39) for real-time monitoring of the PCR
signal and was labeled with a 59-FAM reporter, an internal ZEN
quencher and a IowaBlack Fluorescent Quencher at the 39-end
(IDT, Leuven, Belgium). The amplicon size was 96 base pairs.
Real-time PCR
The draPCR was performed with a 25 mL reaction mix
containing 5 mL DNA, 16 Perfecta qPCR Supermix (Quanta
Biosciences), 500 nM of Sh-FW and Sh-RV primer, 250 nM of
Sh-probe and 0.1 mg/mL bovine serum albumin. The program
consisted of an initial step of 2 min at 95uC followed by 50 cycles
of 15 s at 95uC and 60 s at 60uC.
The reaction was run on the SmartCycler II (Cepheid Benelux,
Belgium). DNA detection was expressed by Cycle threshold (Ct)-
values. In every run, the non-template control was negative
(Ct = 0) and the S. haematobium control was positive.
To detect DNA of schistosome species other than S. haematobium,
the Sm1-7PCR and genusPCR were performed as described
before [7,10].
PCR validation
The primer and probe design was verified with Integrated DNA
Technology (IDT) Oligo Analyzer software (v3.1) (http://eu.
idtdna.com/analyzer/Applications/OligoAnalyzer/). Primer and
probe specificity was checked in silico by BLAST analysis (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) and by 2% agarose gel electro-
phoresis at 100 V for 35 minutes.
The analytical specificity of the PCR was tested on a panel of
clinical control samples containing 23 different intestinal or blood
parasites. The panel included stool samples (n = 14) from patients
infected with protozoa (Giardia lamblia, Entamoeba dispar, E.
histolytica, Blastocystis hominis, Enterocytozoon bieneusi, Encephalitozoon
spp), nematodes (Ascaris lumbricoides, Strongyloides stercoralis, Tricho-
strongylus spp., Trichuris trichiura, or Ancylostomidae), trematodes
Author Summary
Schistosomiasis is a disease caused by parasitic worms of
the genus Schistosoma. About 200 million people are
affected worldwide. Also travelers are at risk as even a brief
contact with infested freshwater can cause infection. S.
mansoni and S. haematobium are the two main species
that are identified in travelers and migrants. The eggs of
these parasites are respectively excreted in feces and urine,
and the diagnosis relies mostly on microscopy. In travelers,
infections are easily missed due to low worm load or
because egg excretion is not yet started upon arrival.
Consequently, there is need for sensitive diagnostic tools
that can be used in the early stage of infection. A
previously published study reported the ability to detect S.
mansoni DNA in serum by real-time PCR. To enable the
diagnosis of urogenital schistosomiasis, we developed a
PCR to detect S. haematobium DNA in serum. We
demonstrated that the latter PCR is more sensitive than
microscopy when applied on feces and urine, and, when
performed on serum, particularly useful to confirm
diagnosis during acute urogenital schistosomiasis. We
comment on the plausible origin of parasite DNA in
relation to the different life cycle stages present in the
blood circulation.
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(Clonorchis spp., Fasciola hepatica) or a cestode (Taenia saginata) and
blood samples (n = 9) from patients infected with Plasmodium
falciparum, P. vivax, P. ovale, P. malariae, Leishmania donovani, Loa loa,
Onchocerca volvulus, Dirofilaria repens or Trypanosoma brucei rhodesiense.
The detection limit was determined on a 10-fold dilution series
of a stool sample containing 580 EPG of S. haematobium. It was
diluted in a negative stool sample which was dissolved in ASL
buffer (Qiagen). DNA was extracted from each dilution and the
highest dilution with a positive signal indicated the detection limit.
The variation in Ct-values was determined in a serum sample
that was processed 8 times within the same run (repeatability) or 5
reactions that were run at different days (reproducibility). The
coefficient of variation (CV, expressed as %) of the Ct-values was
calculated.
Microscopy
Microscopy was performed on a single urine and/or fecal
sample per patient at the time of presentation and in some cases,
on a single follow-up sample one month after treatment. Diagnosis
of schistosomiasis was confirmed when S. haematobium or S. mansoni
eggs were detected in urine and/or feces.
Microscopic examination of urine samples was performed on
the sediment of at least 20 mL end-stream urine and of stool
samples following a concentration method on 3 grams of feces that
had been homogenized in 42 mL of 10% formaldehyde-saline
solution [16]. The infection intensity in stool was expressed by the
number of EPG. The limit of detection was 10 EPG.
Serology
A combination of an in-house enzyme-linked immunosorbent
assay (ELISA) using S. mansoni antigen (mixture of egg and adult
worm extract) and an indirect hemagglutination inhibition assay
(IHA), using a S. mansoni adult worm extract (ELI.H.A. Schisto-
soma, EliTech MICROBIO, France) with a cut-off at 1/160, were
used to detect anti-schistosome antibodies.
Results
Primer and probe design
IDT Oligo analysis approved no self- or heterodimerization
between the primers and the probe. BLAST analysis with probe
and primers indicated 100% query coverage and maximum
identity with S. haematobium. No species other than Schistosoma were
in silico recognised by the primers and probe. Gel electrophoresis
obtained a single band of expected length for the amplicon of S.
haematobium and no signal for the non-template control.
PCR validation
To determine the species-specificity, schistosome species of the
three complexes were tested with the draPCR, the Sm1-7PCR and
the genusPCR. The DNA controls of human species of the S.
haematobium complex revealed a strong signal with the draPCR (Ct-
values ranging from 15.21 to 16.65) and the cattle species S. bovis
revealed a signal of medium intensity (Ct 29.68). DNA controls of
other Schistosoma species gave no (S. japonicum, S. mekongi) or a very
weak signal (S. mansoni, Ct 41.93) (Table 1). In comparison, the
genusPCR easily recognized all species of the three complexes
while the Sm1-7PCR detected a strong signal for S. mansoni and S.
bovis, a medium to weak signal for the human species of the S.
haematobium complex and no signal for species of the S. japonicum
complex (Table 1).
Of interest is the difference in Ct-values measured for S.
haematobium (Ct 15.21) and S. mansoni (Ct 41.93) by the draPCR.
Since the amount of amplicon doubles every PCR cycle (i.e.
increase by one log2), the difference of 26 Ct’s is equivalent to a
more than 67 million times lower sensitivity to detect S. mansoni in
comparison to S. haematobium. The same counts for the detection of
the S. bovis species in comparison to the other S. haematobium
complex species by the draPCR with a difference of 14 Ct’s that
accounts for a 16,000 times lower sensitivity (Table 1).
No cross-reaction was seen with the draPCR in the 23 control
samples with intestinal and blood parasites other than Schistosoma.
The analytical sensitivity demonstrated a detection limit of 0.5
EPG.
Repeatability and reproducibility testing revealed a CV of
1.03% and 1.04% respectively.
PCR analysis on urine samples and biopsy
A panel of 110 urine samples and one bladder wall biopsy was
analysed with the draPCR. A positive PCR signal was obtained in
14 urine samples (Ct-values ranging from 16.77 to 32.40) of which
seven were positive for S. haematobium ova by microscopy (Table 2).
The other seven urine samples (Ct-values ranging from 30.74 to
46.63) were from patients treated for schistosomiasis two weeks or
one month before (n = 2) or from patients without previous
treatment but with anti-schistosome antibodies (n = 3) or with S.
haematobium eggs in feces (n = 1) or in a urine sample obtained three
days earlier (n = 1). The latter urine sample also contained
Trichomonas vaginalis. The 96 urine samples that were negative for
S. haematobium or any other parasite by microscopy, were also
negative by PCR (Table 2).
The biopsy containing S. haematobium eggs was positive by PCR
with a Ct-value of 17.08.
PCR analysis on stool samples
The draPCR was evaluated on a panel of stool samples in which
eggs of S. haematobium (n = 11), of S. mansoni (n = 21) or no
schistosome eggs (n = 52) were microscopically detected. All
samples with eggs of S. haematobium were positive (Ct-values
ranging from 20.35 to 37.87) and all samples with eggs of S.
mansoni were negative (Table 3). In addition, the draPCR revealed
a positive signal in three samples without eggs (Ct-values varied
from 36.78 to 45.33), two of which were follow-up samples of
confirmed patients one month after treatment and one from a
clinically suspected patient with eosinophilia.
PCR analysis on serum
There is no reference method for schistosome DNA detection in
serum. We therefore used the level of evidence of infection
(confirmed S. haematobium (n = 12) or S. mansoni infection (n= 20) or
suspected cases (n = 64)) as a reference (Table 4). Of all suspected
cases, 8/64 were migrants and 56/64 travelers of whom serum
was collected within 12 weeks upon return in 39 travelers and after
more than 12 weeks (varying from 91 to 336 days) in 17 travelers.
In total, 135 serum and blood samples were analysed from 96
patients of whom 64 patients with a single serum sample and 32
patients with one or more follow-up samples. No discordant results
were obtained in different samples from the same patient.
The draPCR was positive in 27 samples from 13 patients of
which 11 patients (22 samples) with a microscopic confirmed S.
haematobium infection and two patients (5 samples) with a clinical
suspicion based on the presence of eosinophilia (0.88 and 2.13
10*9/L) and anti-schistosome antibodies (IHA 1/160 and 1/640)
(Table 4). Of all 22 PCR positive samples of individuals with a
confirmed S. haematobium infection, all serum samples collected at
the same date of the parasitological confirmation (n= 11), were
positive. All follow-up serum samples obtained 14 to 96 days after
treatment (n = 10 from 8 patients), were also positive by PCR but
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demonstrated higher Ct-values. In two of the 8 patients, both
serological tests remained negative 1 month and 2 months after
treatment.
PCR was additionally positive on one serum collected about 5
weeks after exposure (n = 1) while at that moment the urine and
feces were microscopically negative and no antibodies could be
detected. Detection of ova 42 days later, confirmed the S.
haematobium infection.
In one serum sample from a patient for which a single S.
haematobium egg was detected in urine 514 days after treatment, no
PCR signal was observed but the analysis was performed on an
insufficient volume of serum (1 mL instead of 2 mL). All other
serum samples with a negative PCR signal were from patients with
a confirmed S. mansoni infection (20 patients, 22 samples) or from
clinically suspected patients without schistosome eggs in urine and
feces (62 patients, 85 samples) (Table 4). Four of these suspected
patients had microscopically confirmed infections with Ascaris
lumbricoides (n = 1), Ancylostomidae (n = 1), Strongyloides stercoralis (n = 1)
or Trichuris trichuria (n = 1) and nine had been treated 6 months to 3
year prior to serum collection. The 85 PCR negative samples
showed schistosomal antibodies by ELISA (n= 4), IHA (n= 10) or
both (n= 15) and/or belonged to patients suspected because of
recent freshwater exposure or eosinophilia.
Discussion
Urogenital schistosomiasis remains an important public health
problem affecting approximately 112 million people, about half of
the worldwide schistosome infections [2]. Schistosomiasis import-
ed by travelers, expatriates and migrants is often caused by S.
haematobium, with a frequency in the same range to that of S.
mansoni [6,17–19].
The presently developed PCR was designed to be used as a
highly sensitive diagnostic tool for urogenital schistosomiasis in
travelers returning from endemic regions. We opted for a real-time
PCR format which has a short turn-over time and is preferred over
conventional PCR methods due to its lower risk of contamination
and higher sensitivity [20,21]. The latter is of particular interest in
travelers as they have often low parasite loads in the acute phase
[6], rendering confirmation by microscopy erratic. The draPCR
was able to detect all microscopy-confirmed S. haematobium
infections in urine, bladder wall biopsy and feces and demon-
strated no cross-reaction in clinical samples with microscopy-
confirmed S. mansoni and other intestinal or blood parasites.
Moreover, the draPCR detected ten extra S. haematobium-positive
samples (7 urine and 3 stool samples) from 8 non-egg excretor
patients that were highly suspected for urogenital schistosomiasis
based on recent freshwater exposure, a strong antibody response
(IHA$1/1280) and/or the presence of eosinophilia. This confirms
previous findings that PCR is highly sensitive in urogenital
schistosomiasis diagnosis [22–24]. The draPCR can be of value on
urine and stool samples of suspected patients when no eggs can be
demonstrated by microscopy, especially as sampling is not
invasive. Alternatively, the genus-specific PCR [7] could be used
on urine and feces enabling the detection of schistosome DNA,
regardless the causal species.
Besides the excellent performance of the draPCR on urine and
stool samples, the most striking result of this study is the specific
detection of S. haematobium in serum. All but one of the serum
samples from patients with a confirmed S. haematobium infection,
and none of the serum samples from patients with a confirmed S.
mansoni infection, were positive with the draPCR. Schistosomal
DNA could additionally be detected in the serum of one patient
about 5 weeks after freshwater exposure and 42 days before
confirmation of the S. haematobium infection by microscopy. This
clearly demonstrates the diagnostic potential of the draPCR to
detect S. haematobium in serum during the acute phase of the
infection.
Table 1. Species-specificity of the draPCR in comparison to the Sm1-7PCR and the genusPCR.
complex species host extract from draPCR Sm1-7PCR genusPCR
S. mansoni complex S. mansoni human adult worm 41.93* 15.08 21.35
S. haematobium complex S. haematobium human adult worm 15.21 29.44 20.67
S. intercalatum human adult worm 16.65 39.16 23.64
S. guineensis human adult worm 15.12 38.97 23.26
S. bovis cattle adult worm 29.68 13.49 18.92
S. japonicum complex S. japonicum human cercariae 0.00 0.00 23.52
S. mekongi human clinical sample 0.00 0.00 27.98
Ct-values indicate a strong (Ct,28, highlighted in bold), medium (Ct between 28–38), weak (Ct.38) or no (Ct = 0) recognition of the species.
*a 5-fold dilution series on this DNA demonstrated that the weak signal resulted from cross-amplification and not from a-specific background noise.
doi:10.1371/journal.pntd.0002413.t001
Table 2. Evaluation of the draPCR on urine samples.
Microscopy (urine)
Dra PCR S. haematobium negative Total
positive 7 7 14
negative 96 96
Total 7 103 110
doi:10.1371/journal.pntd.0002413.t002
Table 3. Evaluation of the draPCR on feces.
Microscopy (feces)
DraPCR S. haematobium S. mansoni negative Total
positive 11 3 14
negative 21 49 70
Total 11 21 52 84
doi:10.1371/journal.pntd.0002413.t003
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One serum sample of a patient with a confirmed S. haematobium
infection was negative, which could be explained by previous
treatment or the rather low volume (1 mL) of serum analysed. Due
to the retrospective design of this study, PCR could not always be
performed on an adequate volume of serum. We consider 2 mL as
the optimal volume required for analysis.
Two extra S. haematobium infections were detected by the
draPCR in serum samples of suspected patients. False-positivity by
PCR seems very unlikely as both patients had recent exposure to
freshwater in Mali, developed typical severe symptoms related to
Katayama syndrome with hypereosinophilia and had a positive
serological response five to eight weeks post-exposure. Moreover,
S. haematobium DNA was also detected in the follow-up serum
samples while urine and feces remained negative after treatment.
The decreasing PCR signal in follow-up samples demonstrates the
PCR’s potential to semi-quantitatively monitor treatment. Extra
studies are required to confirm this. Further research could
additionally compare the persistence of detectable levels of parasite
DNA in serum with levels of circulating antigen that are more
related to the actual worm burden and rapidly decrease after
treatment [25]. Also, more scientific data is needed to assure when
parasite DNA is cleared from the blood stream after treatment in
order to determine the discriminating power of PCR between
active or past present infections with the same Schistosoma species.
PCR positivity was seen until at least 3 months after treatment in
the present study, and up to more than one year after treatment in
patients with S. mansoni infections [10].
A drawback of this study is that we had no genital samples
available to test with the draPCR. S. haematobium parasites can
cause genital schistosomiasis [1,26] but in travelers, only few
cases were reported [26,27]. Only one bladder wall biopsy was
tested, and although this does not allow drawing conclusions, it
is worth to mention that examination of tissue samples by PCR
might be helpful to diagnose schistosomiasis in non-egg excretor
individuals. Another drawback is that due to the retrospective
sample collection, early acute phase samples were not frequently
available because antibody or egg detection followed weeks
later. A prospective study is needed with selection of patients
during the (early) acute phase in order to compare the
performance of different tools for urogenital schistosomiasis
diagnosis [24].
The PCR targets Dra1, a sequence specific for S. haematobium
[13] and previously successfully used in a conventional PCR on
cercaria and infested snails [28] and on urine [24]. Similar to the
Sm1-7 121-bp tandem repeat sequence that comprises 11% of the
S. mansoni genome [8,10,29] and to the multicopy retrotransposon
gene representing 14% of the S. japonicum genome [30], Dra1 also
has a highly repetitive nature and represents 15% of the S.
haematobium genome [13]. The presence of multiple copies of this
target sequence enables the highly sensitive detection of S.
haematobium DNA in serum and probably explains why the single
copy 28S gene used in the genusPCR [7] was not successful to
detect schistosome DNA in this matrix.
The findings of this study demonstrate that the draPCR for
detection of S. haematobium infections in serum is complementary to
the Sm1-7PCR that is most sensitive to detect S. mansoni infections
[9–10]. Furthermore, we demonstrated the species-specificity of
both PCRs in control DNA of adult worm extracts. Apart from the
strong signal for the human species of the S. haematobium complex
group, we also observed a very weak signal for S. mansoni with the
draPCR and a weak signal for S. haematobium with the Sm1-7PCR.
This can be explained by the fact that the highly repetitive
sequences of S. haematobium or S. mansoni respectively, are most
likely present in at least a single copy in the genome of other
Schistosoma species [13] and are only detectable when a huge
amount of parasite DNA is present as in the case of the adult worm
extracts. Since we did not detect a signal with the draPCR in all 43
clinical samples of patients with confirmed S. mansoni infections
(egg load varying between 10 and 120 EPG), we conclude that the
draPCR and Sm1-7PCR are suitable for analysis of serum of
patients suspected for urogenital and intestinal schistosomiasis,
respectively.
What do we detect by the draPCR in serum, urine and feces?
In analogy with prenatal diagnostics and oncology [31,32],
Wichmann et al [10] used the term ‘cell-free parasite DNA’ (CFPD)
to comprise the DNA that was detected in serum. Indeed, due to the
high parasite turnover, diverse stadia of the parasite might be
present in the blood circulation and are detectable depending on the
phase of the infection. Once penetrated through the human skin,
schistosomules travel with the venous circulation to the lungs within
7 to 10 days and thereafter to the liver region for maturation [1]. In
the acute phase of urogenital infections, the draPCR probably
detects DNA of degrading schistosomules or juvenile worms that did
not survive or mate. Schistosomes are complex multicellular
eukaryotes, and the schistosome DNA in serummight also originate
from rapid turn-over of the tegument during maturation of the
worm [33]. In addition, after the upstream migration of mature
worms to the venous plexus of the bladder and deposition of eggs,
DNA of eggs that circulate into the systemic circulation due to
retrograde venous flow could be detected. In chronic infections,
DNA from desintegrated eggs, or from killed worms after treatment
could also be a target for PCR in serum.
In urine samples, the PCR primarily detects DNA from S.
haematobium eggs. It is not unlikely that also transrenal nucleic acids
Table 4. Evaluation of the draPCR on serum.
Infection status Number of serum samples (number of patients)
DraPCR confirmed S. haematobium confirmed S. mansoni Suspected Total
positive 22 (11)
$ 5 (2)# 27(13)
negative 1 (1)* 22 (20) 85 (62) 108 (83)
Total 23 (12) 22 (20) 90 (64) 135 (96)
$
Of the 22 samples, 11 serum samples were obtained at the moment of egg detection, one sample before egg detection, and 10 samples after treatment. Of the 11 patients
with a confirmed S. haematobium infection, 7 patients demonstrated eggs in urine (see Table 2) and 4 patients had eggs in feces (part of the group described in Table 3).
*only 1 mL of serum was available for PCR analysis and it was obtained 514 days after treatment.
#2 samples were collected before treatment, and 3 samples were taken 21 to 75 days after treatment.
doi:10.1371/journal.pntd.0002413.t004
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of breakdown products of the parasite are detectable in the urine
as demonstrated before for S. mansoni [34,35] and other parasitic
infections [36,37]. In feces, DNA of S. haematobium eggs can be
found due to the atypical location of the worm in the colon or
rectal wall, or due to contamination of the stools with urine in case
of a high-intensity infection [1,38].
So far, no S. haematobium-specific PCR has been described before
to be used in human serum of recently infected travelers. Our
findings suggest that the draPCR in serum is suitable for diagnosis
of urogenital schistosomiasis in a non-endemic setting and might
be of value in diagnosing travelers during the acute phase of
infection (4 to 6 weeks after exposure to infested water) before eggs
excretion and seroconversion, and in light infections. Serology
tests turn positive only about 6 to 12 weeks after exposure [6]. In
addition, weak positive serological reactions are difficult to
interpret and false-negative tests occur, especially with S.
haematobium [4,39,40]. Further prospective evaluation of the
draPCR on serum samples is needed, to demonstrate its diagnostic
role during the early acute phase of the infection.
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